An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology

This week on This Week in Diabetes & Endocrinology, from Hormone Insight: thefirst large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of theweight loss. It is the word oral.Also this week:- A 112,000-patient ACP network meta-analysis that keeps semaglutide and tirzepatide on top for both weight loss and cardiovascular outcomes- A provocative real-world comparison of bariatric surgery versus semaglutide in fatty liver disease- The 2026 ADA Standards of Care, which make cardiovascular and kidney protection a co-primary goal alongside A1C- A Hormone Classic revisit of UKPDS that explains why that shift had to happenOne question runs through all of it: does this change Monday clinic?Chapters00:00 Cold open00:42 This week01:13 Trial of the Week: orforglipron (ATTAIN-2)04:29 Quick Hit: ACP weight-loss drug meta-analysis05:21 Quick Hit: surgery vs semaglutide (MASLD)06:21 Guideline & FDA Watch: 2026 ADA Standards07:27 Hormone Classics: UKPDS08:26 The Bottom Line08:57 Sign-offReferences and written summary: hormoneinsight.com/[slug]For healthcare professionals. Educational, not individual medical advice.Subscribe for a new episode every Saturday.#diabetes #endocrinology #GLP1 #obesity #ADA2026